Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
- Sandoz plans to acquire worldwide product rights for Mycamine®(micafungin sodium) from Astellas
- Acquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolio
- Addition of Mycamine®will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies
Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas.
Closing is anticipated in the course of H1, 2023, subject to standard conditions and regulatory approvals.
Astellas reported Mycamine® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2022. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.
Sandoz CEO Richard Saynor said: “Acquiring this leading and respected global brand will significantly reinforce the Sandoz global hospital offering, as well as complement our existing global leadership position in generic antibiotics.”
He added: “This will also be an important addition to our growing portfolio of anti-infective therapies aimed at combatting the spread of antimicrobial resistance, by providing the right drug to the right patient at the right time.”
Sandoz Anti-Infectives global medical lead Nicholas Adomakoh said: “Modern medicine is increasingly characterized by the need for complex interventions involving highly vulnerable patients. This welcome and timely portfolio addition will allow us to respond even better to the needs of patients and clinicians across the healthcare continuum.”
Mycamine® is a leading global echinocandin, one of three major classes of antifungal agents, with a global patient base of well over two million. It is a therapy of choice in hospitals and intensive care units worldwide, a proven prophylactic in hematology and oncology patients, and widely used in organ transplants.
Mycamine® is indicated for treatment of invasive candidiasis and espophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
# # #
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2021 sales of USD 9.6 billion.
Sandoz on social media:
CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/
|Sandoz Global Communications|
|Chris Lewis||+49 174 244 9501||Leslie Pott||+1 609 627 5287|
|Novartis Media Relations|
|Richard Jarvis||+41 79 584 2326||Julie Masow||+1 862 579 8456|
|+41 79 619 2035|
|Novartis Investor Relations|
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 345 4440|
|Nicole Zinsli-Somm||+41 61 324 3809||Parag Mahanti||+1 973 876 4912|
|Isabella Zinck||+41 61 324 7188|
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Opsigelse af aftale med Kapitalforeningen BLS Invest29.3.2023 09:30:00 CEST | pressemeddelelse
Som følge af ny forretningsmodel har Nykredit Portefølje Administration A/S besluttet at opsige aftalen mellem selskabet og Kapitalforeningen BLS Invest. Aftalen vil ophøre senest ved udgangen af 2024. Nykredit Portefølje Administration A/S vil fortsat varetage forvaltningen af foreningen i opsigelsesperioden i henhold til aftalen. Yderligere spørgsmål kan rettes til pressechef Rikke Gredsted Seidenfaden, tlf. 27 58 95 88. Med venlig hilsen Nykredit Portefølje Administration A/S Erling Skorstad Tage Fabrin-Brasted Adm. Direktør Direktør
Opsigelse af aftale med Investeringsforeningen Investin29.3.2023 09:30:00 CEST | pressemeddelelse
Som følge af ny forretningsmodel har Nykredit Portefølje Administration A/S, besluttet at opsige aftalen mellem selskabet og Investeringsforeningen Investin. Aftalen vil ophøre senest ved udgangen af 2023. Nykredit Portefølje Administration A/S vil varetage administrationen af foreningen i opsigelsesperioden. Yderligere spørgsmål kan rettes til pressechef Rikke Gredsted Seidenfaden, tlf. 27 58 95 88. Med venlig hilsen Nykredit Portefølje Administration A/S Erling Skorstad Tage Fabrin-Brasted Adm. Direktør Direktør
Midaxo Expands Cloud-Native M&A Platform to Support All Forms of Corporate Dealmaking29.3.2023 09:07:00 CEST | Press release
Corporate development teams can now find, evaluate, and deliver deal value faster on the first purpose-built Corporate Development Cloud BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Midaxo, provider of the leading software platform for corporate dealmaking, today announced the launch of the new Midaxo Corporate Development Cloud. After a decade as the leading software solution for companies managing their M&A activity, Midaxo now supports the entire global corporate development team across all deal types to enable them to find, evaluate, and deliver deal value faster and more efficiently than ever before. Built on a foundation of AI, machine learning (ML), and process automation, the Midaxo Corporate Development Cloud simplifies and accelerates corporate dealmaking processes and provides centralized oversight across all deal pipelines. The new Midaxo platform leverages learnings from over 500 Midaxo customers that have completed more than 5,000 transactions worth in excess of $1 trillion
Notification of managers and closely related parties’ transactions with A.P. Møller - Mærsk A/S shares in connection with share buy-back program29.3.2023 08:50:55 CEST | Press release
In connection with the announced share buy-back program in A.P. Møller - Mærsk A/S, A.P. Møller Holding A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Attachment APMM Share buy-back APMH sale 28032023
Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med A.P. Møller - Mærsk A/S aktier i forbindelse med aktietilbagekøbsprogram29.3.2023 08:50:55 CEST | pressemeddelelse
I forbindelse med det annoncerede aktietilbagekøbsprogram i A.P. Møller - Mærsk A/S sælger A.P. Møller Holding A/S løbende aktier pro rata og markedet informeres følgeligt herom - se vedhæftede fil. Vedhæftet fil APMM Aktietilbagekøbsprogram APMH salg_28032023